Item 7.01.Regulation FD Disclosure.

Announcement of Preclinical Data

On May 22, 2023, NeuBase Therapeutics, Inc. (the "Company") conducted a webcast and conference call with investors to discuss a broad set of preclinical safety and efficiency data for its Stealth Editors™ development program. The presentation materials for the webcast and conference call and the Company's press release related to these data are furnished herewith as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K (this "Current Report"). The webcast presentation will be archived and accessible at https://ir.neubasetherapeutics.com/news-events/ir-calendar.

The information contained in this Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2 hereto, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Item 7.01 of this Current Report.

Item 9.01.Financial Statements and Exhibits.



(d)Exhibits

     Exhibit Number    Description
     99.1                Preclinical Data Presentation Materials for webcast and
                       conference call held on May 22, 2023
     99.2                Press Release, dated May 22, 2023
     104               Cover Page Interactive Data File (embedded within the Inline
                       XBRL document)

© Edgar Online, source Glimpses